Truist lowered the firm’s price target on Treace Medical (TMCI) to $9.50 from $10 and keeps a Hold rating on the shares after its recent non-deal roadshow with CEO John Treace. Discussions mostly centered on Lapiplasty competition and new MIS Osteotomy launches, which – along with higher Lapiplasty reimbursement – should allow revenue growth to re-accelerate back to 10% ore more in Q2-Q4, the analyst tells investors in a research note. The firm remains on hold however pending greater confidence that new rollouts can sustain double-digit growth beyond easy 2025 comps, Truist adds.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI: